Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people starting semaglutide notice that familiar smells feel different — stronger, off-putting, or simply strange. This shift in smell sensitivity is not listed as a common side effect in the Wegovy summary of product characteristics, but it is reported by patients and has a plausible biological explanation rooted in the same gut-brain changes that drive the medicine's appetite effects. It is rarely serious, though it can be unsettling. Here is what is known, what is less certain, and what to do if it is affecting you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide works by activating GLP-1 receptors, which are found throughout the brain and gut, not just in the cells that manage blood sugar. GLP-1 receptors are present in regions of the brain involved in appetite regulation and, critically, in areas that process reward and sensory input, including olfactory pathways. When semaglutide engages these receptors, it can subtly alter how the brain weighs and interprets incoming sensory signals, smell included.
There is a second, more immediate pathway worth understanding: nausea. The NHS medicines page for semaglutide lists nausea as one of the most common side effects, particularly early in treatment. Nausea and smell perception are tightly linked in normal physiology, that is why certain cooking smells become unbearable when you are already feeling sick. For many people, what they describe as Wegovy smell sensitivity is, at least partly, nausea reframing ordinary odours as aversive. The two experiences feed each other.
This does not mean the experience is imagined. It means the mechanism is indirect as much as direct, and that matters for how you manage it. You can read more about the wider range of sensory changes some patients notice on our page about Wegovy and skin sensitivity, which covers a similarly under-documented cluster of reports.
The timing is usually the clearest clue. Reports of altered smell on semaglutide tend to cluster around two points: the first few weeks of treatment, when the body is adjusting to any dose, and the days following each dose increase. This mirrors the pattern for gastrointestinal side effects (nausea, reflux, burping) which are themselves most prominent at those same transition points.
Practically, people describe a range of experiences. Some report that meat smells wrong or off, which can suppress appetite further. Others find strongly scented cleaning products, perfume or cooked food suddenly overwhelming. A smaller number notice a change in their own sense of their personal scent, which can feel disorienting. These reports are consistent with what our prescribers at the nume clinical team hear from patients transferring from other services.
The pattern typically settles. As GI side effects stabilise (usually within one to two weeks of a stable dose) smell sensitivity often eases alongside them. If yours has not improved after a few weeks at a steady dose, that is worth raising with your prescriber rather than waiting it out alone. Our FAQs cover what to expect from semaglutide's early side-effect timeline if you want a broader picture. You might also find our page on how quickly Wegovy takes effect useful for setting realistic expectations about the adjustment window.
Most changes in smell during semaglutide treatment are benign and self-limiting. There is, however, one situation that requires prompt clinical assessment. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known but infrequent serious risk with GLP-1 medicines. Acute pancreatitis can distort taste and smell, and it presents alongside severe, persistent stomach pain that may extend towards the back, with or without vomiting. If a change in smell coincides with that kind of abdominal pain, seek medical help the same day rather than monitoring at home.
Outside that scenario, report any persistent or worsening sensory changes to your prescriber at your next review, or sooner if they are significantly affecting your quality of life. Suspected side effects (including those not listed in the patient leaflet) can be submitted directly to the MHRA via the Yellow Card scheme, which helps build the real-world safety picture for newer medicines like Wegovy. Doing so is genuinely useful, not just a formality.
It is also worth checking whether any other medicines or supplements started around the same time could contribute. Some antihistamines, for example, are known to affect taste and smell independently of semaglutide. A prescriber can help untangle the likely cause. Our page on the semaglutide overview covers the full side-effect landscape if you want to compare what you are experiencing against the broader picture.
A few adjustments can make the adjustment period more manageable. Eating cold or room-temperature food reduces the intensity of cooking aromas, which tends to help people who find hot meals suddenly overwhelming. Smaller, simpler meals (bland proteins, plain rice, soft vegetables) are easier to tolerate when smell is amplifying the experience of eating. This mirrors standard advice for managing GLP-1-related nausea, because the root cause overlaps.
Ventilating your kitchen during cooking, avoiding strongly scented personal-care products for a few weeks, and stepping outside when smells feel overwhelming are all low-effort ways to reduce sensory load during the peak adjustment window. None of these require stopping treatment. If you spend time outdoors as part of managing symptoms, it is also worth being aware of how Wegovy can affect sun sensitivity, so you can take appropriate precautions in bright conditions.
If smell changes are severe enough to prevent you from eating adequately, tell your prescriber. The dose escalation schedule is a guide, not a fixed track, a prescriber can extend time at a lower dose to allow better tolerance before moving up. The right pace is the one that keeps you comfortable enough to stay on treatment, not the fastest one. For context on how the semaglutide dose journey unfolds, our page on Wegovy gives a factual overview of the treatment pathway. You may also want to review our guidance on Wegovy and light sensitivity, as some patients notice changes to how they perceive bright environments during the same adjustment period.
If you are considering semaglutide for weight management and want to understand whether it is clinically appropriate for you, the right starting point is a conversation with a prescriber. These are prescription-only medicines, and suitability depends on your full health picture. Start your free consultation with our GPhC-registered prescribers, reviewed the same day, with no waiting list.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.